BIT Capital GmbH Raises Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

BIT Capital GmbH lifted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 239.8% in the 4th quarter, HoldingsChannel reports. The firm owned 285,954 shares of the company’s stock after acquiring an additional 201,808 shares during the period. BIT Capital GmbH’s holdings in Viridian Therapeutics were worth $5,482,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. R Squared Ltd bought a new stake in Viridian Therapeutics during the fourth quarter valued at about $26,000. AlphaQuest LLC grew its stake in shares of Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after acquiring an additional 1,519 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Viridian Therapeutics in the 3rd quarter worth approximately $149,000. Quantbot Technologies LP bought a new stake in Viridian Therapeutics during the 4th quarter worth approximately $164,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Viridian Therapeutics during the third quarter valued at approximately $208,000.

Viridian Therapeutics Price Performance

Shares of Viridian Therapeutics stock opened at $14.16 on Thursday. The firm has a market cap of $1.15 billion, a PE ratio of -3.29 and a beta of 1.05. The stock has a 50 day moving average of $16.87 and a 200 day moving average of $19.73. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 12 month low of $11.40 and a 12 month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. On average, research analysts expect that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research report on Monday, December 16th. Royal Bank of Canada boosted their price objective on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Tuesday, December 17th. Needham & Company LLC reiterated a “buy” rating and set a $38.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Finally, Wells Fargo & Company reissued an “equal weight” rating and issued a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $35.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.